This week’s stock of the week is Aurinia Pharmaceuticals Inc. (AUPH). We are going to take a good look at AUPH stock, some recent developments and what the future may bring. Note that we can only relay any data that we can publicly access. We are not professional or expert analysts, we encourage you to do further research if you want to invest in any stocks. If you have any more questions or suggestions about this article or if you have more information we could use, be sure to contact us through the contact page or mail us directly at email@example.com
What is Aurinia Pharmaceuticals
“Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerularsclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES).” –About AUPH
Voclosporin was discovered by Robert T. Foster and his team at Isotechnika
in the mid 1990s. Isotechnika was founded in 1993 and merged with Aurinia Pharmaceuticals in 2013. Initially, voclosporin was a mixture of equal proporations of cis and trans geometric isomers of amino acid-1 modified cyclosporin. Later, in collaboration with Roche in Basel, Switzerland, voclosporin’s manufacturing was changed to yield the predominantly trans isomer which possesses most of the beneficial effect of the drug (immunosuppression) in the treatment of organ transplantation and autoimmune diseases.
Phase II and Phase III
On December 4th, Aurinia reached the primary endpoint for Phase III of the Voclosporin trials for Lupus Nephritis. As they reported these results, AUPH stock doubled in price. In the chart below you can see their current progress for all their trials.
There’s a lot of chatter about AUPH stock getting a takeover offer in the near future. Several sites have written about AUPH stock being a Top Buyout Candidate. The communities are almost entirely agreeable that a buyout will happen in (early) 2020. Buyout prices of double and even triple the current stock price have been mentioned. Most people think that a buyout of $40+ is very likely. But even prices of $60 to $80 have been mentioned! Personally I also think that a buyout is very likely for AUPH and I too believe that a price north of $40 is not out of question. Ever since they announced their Phase 3 results the stock has been steadily climbing up every day. My suggestion is to accumulate now before the buyout undoubtedly takes place.